Lexaria Bioscience Corp — Cash Flow (NASDAQ:LEXX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 2.66 M-3.99 M-4.88 M-5.88 M-4.96 M-10.45 M -8.71 M Cash from investing activities 26.84 K193.88 K-180.64 K-169.61 K-188.6 K-243.02 K -210.31 K Cash from financing activities 2.7 M13.42 M-44.6 K1.59 M—6.05 M 5.17 M Free cash flow 2.63 M-4.07 M-5.01 M-6.05 M-5.15 M-10.55 M -8.71 M

Noticias

レクサリア・バイオサイエンス株主、年次総会で取締役選任と監査役を承認

Lexaria Bioscience shareholders approve board elections and auditor at annual meeting

レクサリアのDehydraTECH、GLP-1薬の副作用を軽減

Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs

Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Abivax (NASDAQ:ABVX), Rich Sparkle Holdings (NASDAQ:ANPA)

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Agios Pharmaceuticals (NASDAQ:AGIO), Capital One Finl (NYSE:COF)

レクサリア・バイオサイエンスの株価目標、H.C.ワインライトが4ドルから1.50ドルに引き下げ

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright

DehydraTECH-セマグルチド、Rybelsuと比較して副作用48%減少

DehydraTECH-semaglutide shows 48% fewer side effects than Rybelsus

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Lexaria Bioscience (NASDAQ:LEXX)

Lexaria Bioscience closes $3.5 million registered direct offering